MedTrace Logo

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)

NCT02088203 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-03-21

No results posted yet for this study

Summary

Safety and tolerability of a soy-protein Russian Tarragon complex versus a placebo.

Conditions

  • Diabetes Prevention

Interventions

DIETARY_SUPPLEMENT

Dose 1

Russian Tarragon Nutrasorb 0.3 g

DIETARY_SUPPLEMENT

Dose 2

Russian Tarragon Nutrasorb 1 g

DIETARY_SUPPLEMENT

Dose 0

Placebo

DIETARY_SUPPLEMENT

Dose 3

Russian Tarragon Nutrasorb 3 g

DIETARY_SUPPLEMENT

Dose 4

Russian Tarragon Nutrasorb 10 g

DIETARY_SUPPLEMENT

Dose 5

Russian Tarragon Nutrasorb 20 g

DIETARY_SUPPLEMENT

Dose 6

Russian Tarragon Nutrasorb 30 g

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Office of Dietary Supplements (ODS)

    collaborator NIH

  • Pennington Biomedical Research Center

    lead OTHER

Principal Investigators

  • Jennifer C Rood, Ph.D. · Pennington Biomedical Research Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02088203 on ClinicalTrials.gov